The Pharma Section 232 Proclamation is Here.
What It Means and Who Gets a Pass.
The Trump Administration moved quickly after announcing its Section 232 pharmaceutical tariffs on April 2, 2026. After a year-long investigation into whether U.S. reliance on imported drugs poses a national security threat, the Commerce Department concluded that it does, and the President acted. The headline number is striking: a 100 percent ad valorem duty on patented pharmaceuticals and active pharmaceutical ingredients (APIs) listed in the proclamation's Annex I. But the details are considerably more complicated, and for many small manufacturers, the operative question is not whether the tariff applies but whether they qualify for one of several significant exemptions.
The Basic Framework
The proclamation establishes a tiered structure based on country of origin and manufacturing commitments. Larger manufacturers named in Annex II face the tariff starting July 31, 2026; everyone else gets until September 29. Companies that have signed or are in-principle agreement on domestic onshoring deals with the Commerce Secretary will see reduced rates, though those rates escalate back to 100 percent by April 2030. Allied trading partners receive preferential treatment: products from Japan, the EU, South Korea, and Switzerland and Liechtenstein face a 15 percent rate, while the United Kingdom lands at 10 percent under a separate pricing agreement. Generics and biosimilars are exempt for now, though Commerce must report to the President within a year on whether that exemption should be revisited.
The Orphan Drug Exemption: Real Protection, Real Uncertainty
For rare disease manufacturers, the most important provision is the zero-tariff carveout for products where all approved indications carry an orphan designation under the Orphan Drug Act. Also exempt are nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and medical countermeasures. On paper, this is substantial relief. In practice, there is a significant catch: to qualify, a product must either originate from a country with a qualifying trade and security framework agreement or meet an urgent United States health need standard. The Administration has not yet defined that standard, and Commerce has not published Federal Register guidance clarifying it. Until that guidance arrives, rare disease companies whose supply chains run through non-treaty countries face real ambiguity about their actual tariff exposure.
The MFN Wildcard
Companies that enter Most Favored Nation pharmaceutical pricing agreements with the Administration receive a separate zero-tariff rate, good through January 20, 2029. The Commerce Secretary retains authority to claw back that benefit if companies fail to meet their pricing commitments. This provision links trade policy directly to the Administration's drug pricing agenda in a way that will complicate strategic planning for manufacturers weighing whether to pursue an MFN agreement. The tariff, in other words, is also a negotiating lever (as reportedly are the GLOBE and GUARD Models).
The bottom line for pharma manufacturers is that this is not a static policy. Exemption eligibility, onshoring incentives, MFN agreements, and pending Commerce guidance all create moving pieces that will shape the real-world tariff burden for individual companies in ways that are not yet fully knowable. Engaging now, before the guidance drops and before the July implementation deadline, is the only way to protect against outcomes that could have been avoided.
